Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Investor Presentation (May 2021)

27 slides from Observe Medical ASA's investor presentation, May 2021

  1. Slide 1: Observe Medical Company Presentation 2021

    OBSERVE MEDICAL Company Presentation 2021 CEO Björn Larsson / CFO Per Arne Nygård May, 2021

  2. Slide 2: Overview

    OBSERVE MEDICAL Overview Nordic based medtech company with global reach Solid platform for growth, commercializing innovative medtech products on a global market –by organic growth and targeted M&A Nordic direct sales operations and expanding distributor network in Europe Sippi® Broad product portfo

  3. Slide 3: Sippi sales enabled through synergistic product portfolio

    OBSERVE MEDICAL COMMERCIAL OPERATIONS Sippi® sales enabled through synergistic product portfolio utilizing a combination of direct sales and distributors Sippi® global sales operations Nordic direct sales operations with portfolio including Sippi® Urine measurement Direct sales in Nordics Sippi® sal

  4. Slide 4: Sippi - the first automated digital urine meter with biofilm control and wireless connectivity

    Sippi® - the first automated digital urine meter with biofilm control and wireless connectivity • Sippi® - the first automated digital urine meter with biofilm control 7

  5. Slide 5: Slide 5

  6. Slide 6: Hourly urine monitoring of patients is one of the last remaining manual monitoring procedures

    Hourly urine monitoring of patients is one of the last remaining manual monitoring procedures in the ICU with significant clinical implications Inaccurate patient data for clinical decisions Time-consuming for staff and compromised ergonomics - reducing clinical capacity Risk of infections - risk fo

  7. Slide 7: ... and Sippi addresses the clinical challenges

    … and Sippi® addresses the clinical challenges Only automated, digital urine meter with wireless data transfer (Sipplink®) to the hospital patient data management system and which detects (Sippsense®) and hinders (Sippcoat®) bacterial biofilm formation – that can lead to urinary infections Improved

  8. Slide 8: Sippi clinical value demonstrated and supported by advisory board

    SIPPI® EVIDENCE Sippi® clinical value demonstrated and supported by advisory board New study at Nya Karolinska Recent doctoral dissertation further Advisory Board supports Sjukhuset, led by Professor Jan van der demonstrates clinical benefits of Sippi® Sippi® clinical and Linden, has in May 2021 sub

  9. Slide 9: Sippi market opportunity

    SIPPI® MARKET OPPORTUNITY Addressing a substantial market supported by key market drivers and COVID-related impact Current market Sippi® value and potential accentuated by market trends and pandemic CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH SIPPI® VALUE FURTHER ACCENTUATED 4 bn NOK ~0,

  10. Slide 10: Sippi commercial rollout plan

    Sippi commercial rollout plan Global launch Current focus: Broader EU launch Clinical roll-out – in Nordics and selected European markets Preparing for accelerated rollout –with key insights from customer interactions & feedback

  11. Slide 11: Sippi commercial rollout plan

    Sippi commercial rollout plan Global launch Broader EU launch Clinical roll-out – in Nordics and selected European markets Accelerating Sippi® rollout when customer access regained H2 2021

  12. Slide 12: 2021 Covid business impact to date

    OBSERVE MEDICAL 2021 Covid business impact to date Q1 Q2 to date Outlook / Next period Covid policies in place, business operations as normal, digital team interactions Tougher restrictions with lockdown on f2f access to Customer access expected to customers, digital be regained gradually during com

  13. Slide 13: The 2021 year to date journey

    OBSERVE MEDICAL The 2021 year to date journey Further strengthening of Nordic sales organization ~15 new Sippi® systems Expanded and strengthened delivered to clinical sites global patent protection Sippi® Increased customer New scientific evidence interactions and feedback published Broad product S

  14. Slide 14: Summary and outlook

    OBSERVE MEDICAL Summary Outlook Nordic based medtech company with global reach Solid platform for growth, commercializing innovative medtech products Continuous roll-out of Sippi® on a global market –by organic growth and targeted M&A systems for clinical use Nordic direct sales, distributor network

  15. Slide 15: Q&A

    Q&A

  16. Slide 16: Thank you!

    Thank you!

  17. Slide 17: Appendix

    Appendix

  18. Slide 18: Management team

    OBSERVE MEDICAL Experienced management team and board Management team Björn Larsson Per Arne Nygård Mikael Löfgren Anders Nachtweij Chief Executive Officer Chief Financial Officer CTO/COO Sales Director Board of directors Terje Bakken Kristin Nyberg Kathrine Gamborg Andreassen Thomas Grünfeld Chairm

  19. Slide 19: Finance calendar

    OBSERVE MEDICAL Finance calendar 20 August Presentation of Q2 and first half year 2021 21 May 3 November Annual General Meeting Presentation of Q3 2021

  20. Slide 20: Condensed Consolidated Statement of Comprehensive Income

    (UNAUDITED FOR THE PERIOD ENDED 31 MARCH) Condensed Consolidated Statement of Comprehensive Income (Amounts in NOK) Q1 2021 Q1 2020 FY 2020 Operating revenues 3 109 505 32 220 2 961 334 Cost of materials 2 265 385 59 320 1 975 121 Gross result 844 121 -27 100 986 212 Employee benefit expenses 4 124

  21. Slide 21: Condensed Consolidated Statement of Financial Position

    (UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Condensed Consolidated Statement of Financial Position (Amounts in NOK) At 31 March 2021 At 31 March 2020 At 31 December 2020 ASSETS Non-current assets Goodwill 33 932 687 33 430 414 36 268 318 Intangible assets 19 520 998 22 641 708 20 965 076 Tangible

  22. Slide 22: Condensed Consolidated Statement of Financial Positions

    (UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Condensed Consolidated Statement of Financial Positions (Amounts in NOK) At 31 March 2021 At 31 March 2020 At 31 December 2020 EQUITY AND LIABILITIES Total equity 6 631 933 14 640 759 20 349 125 Non-current liabilities Non-current lease liabilities 609

  23. Slide 23: Cash Flow Statement

    (UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Cash Flow Statement (Amounts in NOK) Q1 2021 Q1 2020 FY 2020 Cash flow from operating activities Result before tax -4 818 799 -423 943 -36 868 470 Depreciation and impairment 797 637 778 578 3 163 304 Change in net finance, no cash effect -4 065 382 -5

  24. Slide 24: Top 20 Shareholders

    AS OF MAY 4, 2021 Top 20 Shareholders Rank Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4 222 727 25,14 % 21,54 % Norway 2 INGERØ REITEN INVESTMENT COMPANY 3 939 394 23,45 % 20,09 % Norway 3 RO, LARS 1 500 051 8,93 % 7,65 % Norway 4 UBS Switzerland AG 1 417 522 8,44 % 7,23 %

  25. Slide 25: Definitions of Alternative Performance Measures (APM)

    OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Opera

  26. Slide 26: Copyright and Disclaimer

    OBSERVE MEDICAL Copyright and Disclaimer Copyright Disclaimer reliability or completeness of the Copyright of all published material This Presentation includes and is based, Presentation, and neither Observe Medical including photographs, drawings inter alia, on forward-looking information ASA nor a

  27. Slide 27: Observe Medical

    oKeobserve medical

Observe Medical — Investor Presentation (May 2021) on 6ix